Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach. For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment. Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
Anne Chiang is an Associate Professor at Yale University’s School of Medicine and a member of the Yale Cancer Center’s Developmental Therapeutics and Thoracic Oncology Programs. She serves as Chief Network Officer and the Deputy Chief Medical Officer at the Smilow Cancer Hospital at Yale. Chiang earned an MD from Weill Cornell Medical College, a Ph.D. in Molecular Genetics from Harvard University and an A.B. from Princeton University in Molecular Biology.
Roy Herbst is the Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology at Yale University’s School of Medicine. He serves as Chief of Medical Oncology and the Associate Director for Translational Research at the Yale Cancer Center. Herbst earned his B.S. and M.S. degrees at Yale, his M.D. at Cornell University Medical College and his Ph.D. in Molecular Cell Biology at The Rockefeller University. He has authored more than 275 publications, including peer-reviewedjournal articles, abstracts, and book chapters.
Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach. For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment. Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement.
„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich
Zustand: New. In. Artikel-Nr. ria9783030740306_new
Anzahl: Mehr als 20 verfügbar
Anbieter: moluna, Greven, Deutschland
Zustand: New. Artikel-Nr. 702286216
Anzahl: Mehr als 20 verfügbar
Anbieter: preigu, Osnabrück, Deutschland
Taschenbuch. Zustand: Neu. Lung Cancer | New Understandings and Therapies | Anne C. Chiang (u. a.) | Taschenbuch | Current Cancer Research | vi | Englisch | 2022 | Springer | EAN 9783030740306 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu. Artikel-Nr. 124266646
Anzahl: 5 verfügbar
Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich
Paperback. Zustand: Brand New. 270 pages. 9.25x6.10x0.57 inches. In Stock. Artikel-Nr. x-3030740307
Anzahl: 2 verfügbar
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach. For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment. Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement. Artikel-Nr. 9783030740306
Anzahl: 1 verfügbar
Anbieter: Kennys Bookstore, Olney, MD, USA
Zustand: New. Artikel-Nr. V9783030740306
Anzahl: 15 verfügbar